glp-1 and substance use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) disorders: An emerging pharmacotherapeutic target GLP-1 Anti-Obesity Rx and Alcohol

Furthermore, despite GLP-1RAs have consistently contributed to the improvement of PsO severity and systemic inflammation, disentangling metabolic-driven benefits from direct immunomodulatory effects is still a challenge

The BRAT diet approach (bananas, rice, applesauce, toast) is often recommended, but it is terrible for protein intake

Additional areas of investigation Researchers are also studying semaglutide in obstructive sleep apnea (where weight loss significantly improves symptoms), heart failure with preserved ejection fraction (HFpEF), peripheral artery disease, polycystic ovary syndrome, and even addiction disorders

Programs are personalized to fit individual needs

Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes

Glucagon acting at the GLP-1 receptor contributes to -cell regeneration induced by glucagon receptor antagonism in diabetic mice